627 related articles for article (PubMed ID: 33148070)
21. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
Shen C; Zhang Z; Zhang Y
Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
[TBL] [Abstract][Full Text] [Related]
22. Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence.
Sun W; Jiang Z; Jiang W; Yang R
Cancer Treat Res Commun; 2022; 33():100638. PubMed ID: 36184307
[TBL] [Abstract][Full Text] [Related]
23. [Not Available].
Rubio MT; Galaine J; Borg C; Daguindau É
Bull Cancer; 2018 Dec; 105 Suppl 2():S135-S146. PubMed ID: 30686352
[TBL] [Abstract][Full Text] [Related]
24. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.
Hill JA; Seo SK
Blood; 2020 Aug; 136(8):925-935. PubMed ID: 32582924
[TBL] [Abstract][Full Text] [Related]
25. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.
Yang Z; Wang Y
Chin Med J (Engl); 2023 Oct; 136(19):2285-2296. PubMed ID: 37358555
[TBL] [Abstract][Full Text] [Related]
26. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
Zhang P; Zhang Y; Ji N
Front Immunol; 2022; 13():927132. PubMed ID: 35874698
[TBL] [Abstract][Full Text] [Related]
27. T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies.
Tang L; Zhang Y; Hu Y; Mei H
Biomed Res Int; 2021; 2021():6616391. PubMed ID: 33728333
[TBL] [Abstract][Full Text] [Related]
28. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C
Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176
[TBL] [Abstract][Full Text] [Related]
29. Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors.
Esmaeilzadeh A; Hadiloo K; Jabbari M; Elahi R
Life Sci; 2024 Jan; 337():122381. PubMed ID: 38145710
[TBL] [Abstract][Full Text] [Related]
30. Adoptive therapy with CAR redirected T cells for hematological malignancies.
Li S; Yang Z; Shen J; Shan J; Qian C
Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
[TBL] [Abstract][Full Text] [Related]
31. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
32. Challenges and optimal strategies of CAR T therapy for hematological malignancies.
Zhang Y; Xu Y; Dang X; Zhu Z; Qian W; Liang A; Han W
Chin Med J (Engl); 2023 Feb; 136(3):269-279. PubMed ID: 36848181
[TBL] [Abstract][Full Text] [Related]
33. Chimeric antigen receptor-modified T cells: CD19 and the road beyond.
Salter AI; Pont MJ; Riddell SR
Blood; 2018 Jun; 131(24):2621-2629. PubMed ID: 29728402
[TBL] [Abstract][Full Text] [Related]
34. [Advances in immunotherapy of hematological malignancies by using chimeric antigen receptor-modified lymphocytes].
Xu XJ; Zhao HZ; Tang YM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):521-5. PubMed ID: 23628068
[TBL] [Abstract][Full Text] [Related]
35. Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies.
Abbasi S; Totmaj MA; Abbasi M; Hajazimian S; Goleij P; Behroozi J; Shademan B; Isazadeh A; Baradaran B
Cancer Med; 2023 Apr; 12(7):7844-7858. PubMed ID: 36583504
[TBL] [Abstract][Full Text] [Related]
36. [Prospect for chimeric antigen receptor-engineered T cell immunotherapy for solid tumors].
Zhou SY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):490-492. PubMed ID: 30060355
[TBL] [Abstract][Full Text] [Related]
37. Advances in research on factors affecting chimeric antigen receptor T-cell efficacy.
Zhou D; Zhu X; Xiao Y
Cancer Med; 2024 Jun; 13(11):e7375. PubMed ID: 38864474
[TBL] [Abstract][Full Text] [Related]
38. Toxicities associated with immunotherapies for hematologic malignancies.
Leick MB; Maus MV
Best Pract Res Clin Haematol; 2018 Jun; 31(2):158-165. PubMed ID: 29909916
[TBL] [Abstract][Full Text] [Related]
39. CAR-T cell therapy and infection: a review.
Bupha-Intr O; Haeusler G; Chee L; Thursky K; Slavin M; Teh B
Expert Rev Anti Infect Ther; 2021 Jun; 19(6):749-758. PubMed ID: 33249873
[No Abstract] [Full Text] [Related]
40. Expanding the role of CAR T-cell therapy: From B-cell hematological malignancies to autoimmune rheumatic diseases.
Shumnalieva R; Velikova T; Monov S
Int J Rheum Dis; 2024 May; 27(5):e15182. PubMed ID: 38742463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]